0Q1N Stock Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Pfizer Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.10 |
| 52 Week High | US$41.33 |
| 52 Week Low | US$25.61 |
| Beta | 0.57 |
| 1 Month Change | -6.79% |
| 3 Month Change | -8.10% |
| 1 Year Change | -36.50% |
| 3 Year Change | -32.47% |
| 5 Year Change | -32.97% |
| Change since IPO | 49.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0Q1N | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -2.2% | 3.0% | 0.3% |
| 1Y | -36.5% | -2.8% | -0.8% |
Return vs Industry: 0Q1N underperformed the UK Pharmaceuticals industry which returned -2.6% over the past year.
Return vs Market: 0Q1N underperformed the UK Market which returned -0.3% over the past year.
Price Volatility
| 0Q1N volatility | |
|---|---|
| 0Q1N Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0Q1N has not had significant price volatility in the past 3 months.
Volatility Over Time: 0Q1N's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1849 | 88,000 | Albert Bourla | www.pfizer.com |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands.
Pfizer Inc. Fundamentals Summary
| 0Q1N fundamental statistics | |
|---|---|
| Market cap | US$146.43b |
| Earnings (TTM) | US$2.13b |
| Revenue (TTM) | US$58.50b |
68.8x
P/E Ratio2.5x
P/S RatioIs 0Q1N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0Q1N income statement (TTM) | |
|---|---|
| Revenue | US$58.50b |
| Cost of Revenue | US$23.99b |
| Gross Profit | US$34.51b |
| Other Expenses | US$32.37b |
| Earnings | US$2.13b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | 0.38 |
| Gross Margin | 58.99% |
| Net Profit Margin | 3.65% |
| Debt/Equity Ratio | 80.8% |
How did 0Q1N perform over the long term?
See historical performance and comparison